Publication:
Leptin, Both Bad and Good Actor in Cancer.

Loading...
Thumbnail Image

Date

2021-06-20

Authors

Jiménez-Cortegana, Carlos
López-Saavedra, Ana
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Castiñeiras, Jesús
Virizuela-Echaburu, Juan A
de la Cruz-Merino, Luis de la
Sánchez-Margalet, Víctor

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the "obesity paradox", and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology.

Description

MeSH Terms

Adaptive Immunity
Animals
Humans
Immunotherapy
Leptin
Neoplasm Proteins
Neoplasms
Obesity

DeCS Terms

CIE Terms

Keywords

cancer, immune system, immunotherapy, inflammation, leptin, obesity

Citation